From zero to hero: Endocyte’s little deal a year ago spurred a comeback capped by $2.1B Novartis buyout
A year ago, with its stock in the toilet after its lead drug flopped in Phase III, forcing a restructuring, new Endocyte CEO Mike Sherman said everything you would expect a biotech chief to say after completing a small licensing deal for a new lead drug. The $12 million upfront deal with ABX was transformational, he boasted to reporters. It was a blockbuster headed to a multibillion dollar market.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters